Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset

Fineline Cube Jun 8, 2026
Company Deals

Junshi Biosciences Forms Strategic JV with Zhiyu Biomedicine, Contributing Oncology Antibody IP and ADC Platform for Multispecific Development

Fineline Cube Jun 8, 2026
Company Deals

Everest Medicines Licenses LNZ100 Presbyopia Treatment from Corxel for Greater China – Aceclidine-Based Eye Drop Offers Novel Miotic Mechanism

Fineline Cube Jun 8, 2026
Company Deals

SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying – Full IP Transfer in Category 2.2 and 2.3 Assets

Fineline Cube Jun 5, 2026
Company Deals

Lonza and Stipple Bio Forge Strategic ADC Partnership – Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies

Fineline Cube Jun 5, 2026
Policy / Regulatory

China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development

Fineline Cube Jun 5, 2026
Company Drug

Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States

Fineline Cube Jun 8, 2026
Company Drug

Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy

Fineline Cube Jun 8, 2026
Company Drug

Hengrui Pharmaceuticals Gains NMPA Approval for HRS-6719 in Solid Tumors

Fineline Cube Apr 7, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clinical trial...

Company Drug

Sanofi’s Rilzabrutinib Granted Orphan Drug Designation for Rare Diseases

Fineline Cube Apr 7, 2025

Sanofi (EPA: SAN, NASDAQ: SNY) announced that it has received Orphan Drug Designation (ODD) from...

Company Drug

Sunshine Guojian’s SSGJ-627 Gains NMPA Approval for Ulcerative Colitis Trial

Fineline Cube Apr 7, 2025

China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, (SHA: 688336) a subsidiary of 3SBio Inc. (HKG:...

Company Drug

Sarepta and Roche Seek to Resume Elevidys Trials After EMA Halt

Fineline Cube Apr 7, 2025

The European Medicines Agency (EMA) may lift the temporary hold on certain Phase III studies...

Company Drug

Bayer’s Vividion Therapeutics Starts Phase I Study for RAS-PI3Kα Inhibitor

Fineline Cube Apr 7, 2025

German pharmaceutical giant Bayer’s (ETR: BAYN) wholly owned subsidiary Vividion Therapeutics, Inc. has announced the...

Company Deals

ABL Bio and GSK Partner on Neurodegenerative Disease Therapies with Grabody-B Platform

Fineline Cube Apr 7, 2025

South Korea-based clinical-stage biotech ABL Bio Inc. (KOSDAQ: 298380) has entered into a licensing agreement...

Company

BeiGene Halts Ociperlimab Clinical Program for Lung Cancer

Fineline Cube Apr 7, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), the China-based oncology specialist formerly known as...

Company Deals

Eli Lilly Secures Global License for Sangamo’s STAC-BBB Gene Therapy Technology

Fineline Cube Apr 7, 2025

US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has entered into a licensing agreement...

Company Medical Device

MicroPort Endovascular’s Talos Stent Approved in Brazil for Aortic Dissection

Fineline Cube Apr 7, 2025

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) announced that it has received marketing approval...

Company Drug

Fujian Kerui’s Generic Sirolimus Gel Approved by China’s NMPA

Fineline Cube Apr 7, 2025

China-based Fujian Kerui Pharmaceutical Co., Ltd. announced that its generic version of Pfizer’s (NYSE: PFE)...

Company Deals

Johnson & Johnson Completes Acquisition of Intra-Cellular Therapies

Fineline Cube Apr 3, 2025

US-based Johnson & Johnson (NYSE: JNJ) announced the completion of its acquisition of fellow American...

Company Deals Medical Device

Yuewei Medtech Secures RMB100 Million in Series A++ Funding for Cardiac Device Development

Fineline Cube Apr 3, 2025

Beijing Yuewei Medical Technology Co., Ltd, a medical device company specializing in coronary heart disease,...

Company

Boehringer Ingelheim Reports 6.1% Sales Growth in 2024, Bolstered by Key Pharmaceuticals

Fineline Cube Apr 3, 2025

Germany-based Boehringer Ingelheim released its 2024 financial report, recording group net sales of EUR 26.8...

Company Deals

GE Healthcare Partners with Probo Medical to Distribute Ultrasound Devices

Fineline Cube Apr 3, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) has entered...

Company Drug

Henlius Biotech’s HLX04-O Shows Positive Results in wAMD Phase III Trial

Fineline Cube Apr 3, 2025

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced positive results from the Phase III...

Company Drug

Mabwell Bioscience’s 7MW3711 ADC Receives Clinical Trial Approval in China

Fineline Cube Apr 3, 2025

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that it has received clinical trial...

Company Deals

Sinovac Partners with CPMA to Advance Vaccine Preventable Disease Initiatives

Fineline Cube Apr 3, 2025

China-based Sinovac Biotech Ltd (NASDAQ: SVA) has entered into a strategic memorandum of understanding (MoU)...

Company Drug

Novartis’ Vanrafia Gets FDA Accelerated Approval for IgAN

Fineline Cube Apr 3, 2025

Switzerland-based Novartis (NYSE: NVS) announced that it has received accelerated approval from the US Food...

Company Deals

Sanofi and Cathay Capital Launch RMB 2 Billion Pharma Innovation Fund in China

Fineline Cube Apr 3, 2025

The Sanofi Cathy Capital Pharmaceutical Innovation Fund, a joint venture between French pharmaceutical giant Sanofi...

Company Medical Device

Sihuan Pharma’s Polycaprolactone Microsphere Filler Gains NMPA Approval

Fineline Cube Apr 3, 2025

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that it has received Category III...

Posts pagination

1 … 196 197 198 … 679

Recent updates

  • PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset
  • Sino Medical Sciences Secures Colombian Approval for HT Supreme Drug-Eluting Stent – Advanced Dual-Polymer Technology Expands Latin American Presence
  • Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States
  • Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy
  • Bayer’s Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial – First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset

Company Medical Device

Sino Medical Sciences Secures Colombian Approval for HT Supreme Drug-Eluting Stent – Advanced Dual-Polymer Technology Expands Latin American Presence

Company Drug

Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States

Company Drug

Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.